Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
General Radiation Oncology
What kidney dose constraints would you use in a patient s/p nephrectomy requiring total body irradiation?
Related Questions
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
When do you offer adjuvant radiation therapy for a glomus tumor of uncertain malignant potential of the extremity resected with negative margins?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
When do you prefer to use bolus for treating superficial tumors adjacent to or involving the skin surface, especially for complex surface anatomy in the pelvis, head/neck, and extremity regions?
What dose and fractionation would you use for a non-operable solitary fibrous tumor in the lumbar vertebra with definitive intent?
Has there been an observed interaction between ACE inhibitors and development of angioedema in a block demarcated superficial radiation therapy treatment volume (ex. lip)?
Would you ever re-irradiate the groin/inguinal region?
How do you manage a patient's pain from the skin tattoos placed at the CT simulation?
Would involved site radiation therapy be recommended in a patient with POEMS syndrome (including 3 lytic spinal lesions and a liver plasmacytoma) whose myelopathy symptoms worsened after one cycle of CyBorD?
What dose/fractionation would you recommend for a prostate patient who previously received 1 of 5 planned fractions SBRT in 2020?
